Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | PDE6D | O43924 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13008897 | 1.00 | P2RX4 (0.33) | P2RX4FAAHMGLLPDE6DALDH1A1 | |
| SCHEMBL13427225 | 0.97 | P2RX4 (0.35) | P2RX4 | |
| SCHEMBL13428271 | 0.97 | P2RX4 (0.35) | P2RX4 | |
| SCHEMBL13008893 | 0.93 | FAAH (0.35) | P2RX4FAAHMGLLPDE6DALDH1A1 | |
| SCHEMBL13008905 | 0.92 | ESR1 (0.37) | FAAHMGLLPDE6DALDH1A1HSP90AA1 | |
| SCHEMBL13008899 | 0.92 | FAAH (0.36) | P2RX4FAAHMGLLPDE6DALDH1A1 | |
| SCHEMBL13427263 | 0.91 | ESR1 (0.36) | PDE6DALDH1A1HSP90AA1GPR84ESR1 | |
| SCHEMBL13427267 | 0.91 | ESR1 (0.34) | PDE6DALDH1A1HSP90AA1GPR84ESR1 | |
| SCHEMBL13427255 | 0.90 | SMN1; SMN2 (0.33) | PDE6DALDH1A1HSP90AA1GPR84ESR1 | |
| SCHEMBL13428275 | 0.90 | SMN1; SMN2 (0.33) | PDE6DALDH1A1HSP90AA1GPR84ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2256176-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-12-01 | — | — | EP | disclosed |
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-03-04 | — | — | US | disclosed |
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100051106-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | RPL36, RPL39, RPL36A | P2RX4 2539/4885FAAH 3781/4885MGLL 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.